m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03341)
Name
YP-005
Synonyms
D-erythro-Sphingosine-1-phosphate; D-erythro-sphingosine 1-phosphate; DUYSYHSSBDVJSM-KRWOKUGFSA-N; Sphing-4-enine 1-phosphate; Sphing-4-enine-1-phosphate; Sphingosine 1-phosphate; Sphingosine 1-phosphic acid; YVE187NJ1U; sphingosine-1-phosphate; (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate; 26993-30-6; 4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (2S,3R,4E)-; C18-Sphingosine 1-phosphate; CHEBI:37550; CHEMBL225155; S1P; UNII-YVE187NJ1U
    Click to Show/Hide
Status
Phase 1
Structure
3D MOL
2D MOL
Formula
C18H38NO5P
InChI
1S/C18H38NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)17(19)16-24-25(21,22)23/h14-15,17-18,20H,2-13,16,19H2,1H3,(H2,21,22,23)/b15-14+/t17-,18+/m0/s1
InChIKey
DUYSYHSSBDVJSM-KRWOKUGFSA-N
PubChem CID
5283560
VARIDT Drug ID
DR00118
INTEDE Drug ID
DR1811
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for YP-005. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of YP-005 through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for YP-005. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of YP-005 through regulating the expression of P-glycoprotein 1 (ABCB1). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for YP-005. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of YP-005 through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [4]
Sphingosine kinase 1 (SPHK1)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Sphingosine kinase 1 (SPHK1) is a therapeutic target for YP-005. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of YP-005 through regulating the expression of Sphingosine kinase 1 (SPHK1). [5], [6]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem. 2010 Apr 2;285(14):10477-86. doi: 10.1074/jbc.M109.064162. Epub 2010 Jan 28.
Ref 3 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 4 Lipid dependence of ABC transporter localization and function. Chem Phys Lipids. 2009 Oct;161(2):57-64.
Ref 5 ALKBH5 Regulates SPHK1-Dependent Endothelial Cell Angiogenesis Following Ischemic Stress. Front Cardiovasc Med. 2022 Jan 20;8:817304. doi: 10.3389/fcvm.2021.817304. eCollection 2021.
Ref 6 Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem. 2003 Nov 28;278(48):47408-15. doi: 10.1074/jbc.M307687200. Epub 2003 Sep 16.